| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-beta42 Aggregation. | Tirzepatide | — | 2026-05-27 |
| PRECLINICAL | evidence | Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies. | Tirzepatide | — | 2026-05-27 |
| PRECLINICAL | evidence | Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid Blepharoplasty. | Tirzepatide | — | 2026-05-26 |
| PRECLINICAL | evidence | Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics. | Tirzepatide | — | 2026-05-26 |
| PRECLINICAL | evidence | Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis. | Tirzepatide | Liver health | 2026-05-26 |
| PRECLINICAL | evidence | The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. | Tirzepatide | — | 2026-05-26 |
| PRECLINICAL | evidence | Benefits of Incretin Therapy on Ovarian Function: A Scientific Literature Review. | Tirzepatide | Weight & fat loss | 2026-05-25 |
| PRECLINICAL | evidence | Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis. | Tirzepatide | — | 2026-05-25 |
| PRECLINICAL | evidence | To Reenvision and Redefine: Considering the Role of Lifestyle Interventions in the New Era of Second-Generation Obesity Management Medications. | Tirzepatide | Weight & fat loss | 2026-05-25 |
| PRECLINICAL | evidence | Lifestyle First and Lifestyle Always, Does Not Mean Lifestyle Only: Reimagining Cardiometabolic Care in the Era of GLP-1 Receptor Agonists. | Tirzepatide | — | 2026-05-25 |
| PRECLINICAL | evidence | Impact of GLP-1 Receptor Agonists on Chronic Low Back Pain in Patients with Obesity: A Prospective Pilot Cohort Study. | Tirzepatide | — | 2026-05-22 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions-A Systematic Review. | Tirzepatide | Weight & fat loss | 2026-05-22 |
| PRECLINICAL | evidence | Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. | Tirzepatide | Glycemic control | 2026-05-22 |
| PRECLINICAL | evidence | The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms. | Tirzepatide | — | 2026-05-21 |
| PRECLINICAL | evidence | Causes and consequences of discontinuation of GLP1RAs or tirzepatide. | Tirzepatide | — | 2026-05-21 |
| PRECLINICAL | evidence | Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis. | Tirzepatide | — | 2026-05-21 |
| PRECLINICAL | evidence | Efficacy of tirzepatide in glycemic control and weight management in adults with type 2 diabetes: a systematic review and meta-analysis of real-world studies. | Tirzepatide | Glycemic control | 2026-05-20 |
| PRECLINICAL | evidence | DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic fabry disease. | Tirzepatide | — | 2026-05-20 |
| PRECLINICAL | evidence | [Glucagon-like peptide-1 agonists and heart failure]. | Tirzepatide | Glycemic control | 2026-05-20 |
| PRECLINICAL | evidence | Pharmacovigilance Assessment of Thrombotic Adverse Events Linked to GLP-1 Receptor Agonists: Analysis of FAERS Reports from 2020-2025. | Tirzepatide | — | 2026-05-19 |
| PRECLINICAL | evidence | Swiss obesity clinical practice guidance. | Tirzepatide | Weight & fat loss | 2026-05-19 |
| PRECLINICAL | evidence | GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization. | Tirzepatide | Glycemic control | 2026-05-19 |
| PRECLINICAL | evidence | Tirzepatide attenuates neurotoxicity by suppressing inflammation, apoptosis and restoring neurotrophin expression in an Alzheimer's disease-like rat model. | Tirzepatide | — | 2026-05-19 |
| PRECLINICAL | evidence | Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists. | Tirzepatide | — | 2026-05-19 |
| PRECLINICAL | evidence | Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection. | Tirzepatide | — | 2026-05-19 |
| PRECLINICAL | evidence | Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide. | Tirzepatide | — | 2026-05-18 |
| PRECLINICAL | evidence | Searching for New Pharmacological Treatments of Alcohol Use Disorder (AUD): Focus on GLP-1 Receptor Agonists. | Tirzepatide | Addiction & substance use | 2026-05-18 |
| PRECLINICAL | evidence | Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression. | Tirzepatide | Glycemic control | 2026-05-18 |
| PRECLINICAL | evidence | Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference. | Tirzepatide | Lipid & cardiovascular markers | 2026-05-16 |
| PRECLINICAL | evidence | A Case of Prolonged Paralytic Ileus Following a Tirzepatide Overdose in a Patient with Bulimia Nervosa. | Tirzepatide | — | 2026-05-16 |
| PRECLINICAL | evidence | Persistent Adipose Inflammation Despite Metabolic Recovery Reveals Tissue-Specific Immunomodulation by Tirzepatide. | Tirzepatide | — | 2026-05-15 |
| PRECLINICAL | evidence | Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis. | Tirzepatide | — | 2026-05-15 |
| PRECLINICAL | evidence | Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study. | Tirzepatide | — | 2026-05-14 |
| PRECLINICAL | evidence | Glucagon-like Peptide-1 Therapy in Obesity-Related Heart Failure with Preserved Ejection Fraction: Mechanisms, Clinical Evidence, and Implications. | Tirzepatide | — | 2026-05-14 |
| PRECLINICAL | evidence | Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review. | Tirzepatide | — | 2026-05-13 |
| PRECLINICAL | evidence | What obgyns need to know about GLP-1 receptor agonists. | Tirzepatide | — | 2026-05-12 |
| PRECLINICAL | evidence | Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification? | Tirzepatide | — | 2026-05-12 |
| PRECLINICAL | evidence | Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series. | Tirzepatide | Weight & fat loss | 2026-05-08 |
| PRECLINICAL | evidence | Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy? | Tirzepatide | Lipid & cardiovascular markers | 2026-05-07 |
| PRECLINICAL | evidence | Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting. | Tirzepatide | — | 2026-05-07 |
| PRECLINICAL | evidence | Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis. | Tirzepatide | Kidney function | 2026-05-06 |
| PRECLINICAL | evidence | PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC. | Tirzepatide | — | 2026-05-05 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction. | Tirzepatide | — | 2026-05-05 |
| PRECLINICAL | evidence | Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update. | Tirzepatide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | TikTokfluence: The rise of GLP-1 receptor agonists in the age of social media health trends. | Mounjaro | — | 2026-05-01 |
| PRECLINICAL | evidence | Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. | Tirzepatide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Patient-Reported Outcomes in People With Type 2 Diabetes Escalating Dulaglutide or Switching From Dulaglutide to Tirzepatide. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | Tirzepatide | Mood & anxiety | 2026-05-01 |